These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30012567)

  • 21. Metformin Reduces Prostate Tumor Growth, in a Diet-Dependent Manner, by Modulating Multiple Signaling Pathways.
    Sarmento-Cabral A; L-López F; Gahete MD; Castaño JP; Luque RM
    Mol Cancer Res; 2017 Jul; 15(7):862-874. PubMed ID: 28385910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
    Narayanan BA; Narayanan NK; Pttman B; Reddy BS
    Prostate; 2006 Feb; 66(3):257-65. PubMed ID: 16175586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression.
    Simons BW; Durham NM; Bruno TC; Grosso JF; Schaeffer AJ; Ross AE; Hurley PJ; Berman DM; Drake CG; Thumbikat P; Schaeffer EM
    J Pathol; 2015 Feb; 235(3):478-89. PubMed ID: 25348195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen deprivation modulates gene expression profile along prostate cancer progression.
    Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
    Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Capsaicin reduces the metastatic burden in the transgenic adenocarcinoma of the mouse prostate model.
    Venier NA; Yamamoto T; Sugar LM; Adomat H; Fleshner NE; Klotz LH; Venkateswaran V
    Prostate; 2015 Sep; 75(12):1300-11. PubMed ID: 26047020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of tumor-associated macrophages in prostate cancer transgenic mouse models.
    de Groot AE; Myers KV; Krueger TEG; Kiemen AL; Nagy NH; Brame A; Torres VE; Zhang Z; Trabzonlu L; Brennen WN; Wirtz D; De Marzo AM; Amend SR; Pienta KJ
    Prostate; 2021 Jul; 81(10):629-647. PubMed ID: 33949714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A null-mutation in the Znt7 gene accelerates prostate tumor formation in a transgenic adenocarcinoma mouse prostate model.
    Tepaamorndech S; Huang L; Kirschke CP
    Cancer Lett; 2011 Sep; 308(1):33-42. PubMed ID: 21621325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
    Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.
    Ben Sahra I; Laurent K; Giuliano S; Larbret F; Ponzio G; Gounon P; Le Marchand-Brustel Y; Giorgetti-Peraldi S; Cormont M; Bertolotto C; Deckert M; Auberger P; Tanti JF; Bost F
    Cancer Res; 2010 Mar; 70(6):2465-75. PubMed ID: 20215500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior.
    Gueron G; De Siervi A; Vazquez E
    Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):213-21. PubMed ID: 22183772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer.
    Colquhoun AJ; Venier NA; Vandersluis AD; Besla R; Sugar LM; Kiss A; Fleshner NE; Pollak M; Klotz LH; Venkateswaran V
    Prostate Cancer Prostatic Dis; 2012 Dec; 15(4):346-52. PubMed ID: 22614062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phellodendron amurense bark extract prevents progression of prostate tumors in transgenic adenocarcinoma of mouse prostate: potential for prostate cancer management.
    Ghosh R; Graham H; Rivas P; Tan XJ; Crosby K; Bhaskaran S; Schoolfield J; Banu J; Fernandes G; Yeh IT; Kumar AP
    Anticancer Res; 2010 Mar; 30(3):857-65. PubMed ID: 20393007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Montico F; Kido LA; Hetzl AC; Cagnon VH
    Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dietary methionine restriction inhibits prostatic intraepithelial neoplasia in TRAMP mice.
    Sinha R; Cooper TK; Rogers CJ; Sinha I; Turbitt WJ; Calcagnotto A; Perrone CE; Richie JP
    Prostate; 2014 Dec; 74(16):1663-73. PubMed ID: 25250521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen deprivation and stem cell markers in prostate cancers.
    Tang Y; Hamburger AW; Wang L; Khan MA; Hussain A
    Int J Clin Exp Pathol; 2009 Nov; 3(2):128-38. PubMed ID: 20126580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
    Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
    Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer.
    Escara-Wilke J; Keller JM; Ignatoski KM; Dai J; Shelley G; Mizokami A; Zhang J; Yeung ML; Yeung KC; Keller ET
    Prostate; 2015 Feb; 75(3):292-302. PubMed ID: 25327941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
    Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
    Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relaxin promotes prostate cancer progression.
    Feng S; Agoulnik IU; Bogatcheva NV; Kamat AA; Kwabi-Addo B; Li R; Ayala G; Ittmann MM; Agoulnik AI
    Clin Cancer Res; 2007 Mar; 13(6):1695-702. PubMed ID: 17363522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.
    Chen WY; Tsai YC; Yeh HL; Suau F; Jiang KC; Shao AN; Huang J; Liu YN
    Sci Signal; 2017 Aug; 10(492):. PubMed ID: 28811384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.